Modlodal (Modafinil)

Modafinil, the active ingredient in Modlodal, is a eugeroic presented as an oral tablet for oral use. It promotes wakefulness and is prescribed for disorders characterized by excessive daytime sleepiness, such as narcolepsy, obstructive sleep apnea‑related sleepiness, and shift work sleep disorder. GNH USA supplies Modlodal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modlodal, a central nervous system stimulant, is indicated for conditions that affect the sleep‑wake cycle. - Narcolepsy: reduces daytime sleepiness and improves alertness. - Excessive daytime sleepiness associated with obstructive sleep apnea: enhances wakefulness when used alongside primary apnea therapy. - Shift work sleep disorder: helps maintain alertness during scheduled work hours that conflict with normal circadian rhythms.

Adverse reactions may occur with Modlodal use.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Anxiety: feelings of nervousness or tension. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Rash or Stevens‑Johnson syndrome: severe skin reactions requiring immediate medical attention. - Psychiatric symptoms: hallucinations, mania, or depression. - Cardiovascular events: chest pain or arrhythmia. - Liver injury: elevated transaminases or hepatitis.

Before prescribing Modlodal, consider the following safety measures. - Cardiovascular assessment: evaluate history of hypertension, arrhythmia, or ischemic heart disease. - Psychiatric evaluation: monitor for pre‑existing mental health disorders. - Liver function: assess hepatic impairment, as metabolism is hepatic. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Concomitant substances: caution with other CNS stimulants or serotonergic agents. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Modlodal may interact with several medication classes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase modafinil plasma levels. - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): can raise exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: modafinil may reduce efficacy, requiring alternative contraception. - Anticoagulants (e.g., warfarin): may alter INR, necessitating closer monitoring. - Antidepressants (especially SSRIs): potential for increased serotonergic activity.